Akoya Biosciences Inc ( (AKYA) ) has released its Q1 earnings. Here is a breakdown of the information Akoya Biosciences Inc presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akoya Biosciences Inc., known as The Spatial Biology Company®, specializes in spatial phenotyping solutions for the life sciences sector, providing comprehensive single-cell imaging technologies to enhance the understanding of disease progression and therapy response.
In the first quarter of 2025, Akoya Biosciences reported a revenue of $16.6 million, marking a 9.8% decrease compared to the previous year. Despite this decline, the company improved its gross margin to 59.3% and reduced operating expenses by 22.3%, leading to a 37.9% reduction in operating loss. The company also reported a significant decrease in net cash used in operating activities.
Key highlights of the quarter include the selection of Akoya’s PhenoCycler-Fusion platform for a major cancer study and a partnership with the Singapore Translational Cancer Consortium to advance cancer immunophenotyping. Additionally, Akoya launched the largest single-cell spatial proteomics atlas and expanded its biopharma solutions portfolio.
Looking forward, Akoya’s management remains optimistic about the strategic opportunities presented by its pending acquisition by Quanterix Corporation, which is expected to enhance its capabilities in precision medicine. The company continues to focus on innovation and operational discipline to drive future growth.